The Assessa PML digital platform is being piloted in five EU countries as part of a collaborative agreement. The aim is to facilitate the remote transfer, management and storage of MRI scans to more reliably and effectively offer access to reading expertise for the detection of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal disease affecting people living with multiple sclerosis (MS).
The pilot, which includes platform development and on boarding of clinical sites participating in the pilot, has been expanded to include pharmacovigilance reporting — monitoring the effects of medical drugs in order to identify and evaluate previously unreported adverse reactions.
The total contribution paid or to be paid to IXICO and its partners, associated with the scoping, development and pilot stages of this partnership, is in the order of £1.5 million, of which £0.8m has been recognised from project inception to date.
Subject to the timing of the work being performed, the fees payable to IXICO support the Company’s confidence in delivering revenue growth in the financial year ending 30 September 2017.
Giulio Cerroni, Chief Executive of IXICO, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen. The Assessa PML digital platform is intended to provide technology and speciality services to physicians involved in delivering care to people living with MS. PML can be potentially fatal and IXICO is proud to support those involved in its detection.”
